SIR-Spheres® Y-90 resin microspheres were significantly better tolerated than sorafenib in the safety population:
Significantly fewer and less severe Adverse Events (AE)
Significantly fewer patients with treatment-related AEs
Median treatment-related AEs per patient
Significantly reduced frequency and severity of AEs
SIR-Spheres Y-90 resin microspheres were safe and well tolerated, with few SIRT associated complications
There was no treatment related radiation hepatitis or radioembolisation induced liver disease.
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.
Bouattour M et al. Ann Oncol 2017; ESMO 19th WCGIC, Abs. LBA-001.